Andersons pediatric cardiology 661
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.66 KB, 3 trang )
Arecentelegantstudythatevaluatedthe
prevalenceofFHasdetectedthroughuniversal
screeningandhighlightedtheutilityofreversecascadescreeningtoidentifyaffectedparents..
McCrindleBW,UrbinaEM,DennisonBA,etal.
Drugtherapyofhigh-risklipidabnormalitiesin
childrenandadolescents:ascientificstatement
fromtheAmericanHeartAssociation
Atherosclerosis,Hypertension,andObesityin
YouthCommittee,CouncilofCardiovascular
DiseaseintheYoung,withtheCouncilon
CardiovascularNursing.Circulation.
2007;115:1948–1967.
AscientificstatementfromtheAmericanHeart
Associationsummarizingcurrent
recommendationsregardingdrugtherapyfor
high-risklipidabnormalitiesinthepediatric
population..
BraamskampM,LangsletG,McCrindleBW,etal.
Effectofrosuvastatinoncarotidintima-media
thicknessinchildrenwithheterozygousfamilial
hypercholesterolemia:theCHARONstudy.
Circulation.2017;136:359–366.
Arecentimportantstudydemonstratingthe
slowingofprogressionofcIMTinstatin-treated
childrenwithFH,resultinginnosignificant
differenceincIMTbetweenFH-affectedchildren
andtheirunaffectedsiblingsafter2years..
RaalFJ,etal.PCSK9inhibitionwithevolocumab
(AMG145)inheterozygousfamilial
hypercholesterolaemia(RUTHERFORD-2):a
randomised,double-blind,placebo-controlled
trial.Lancet.2015;385(9965):331–340.
TheRUTHERFORD-2Trial:ThisplacebocontrolledRCTstudyofadultswith
heterozygousFH,treatmentwithevolocumab(a
PCSK9inhibitor)resultedinsignificant
reductionsinmeanLDL-Cconcentrationsand
waswelltolerated..
SabatineMS,etal.Evolocumabandclinical
outcomesinpatientswithcardiovascular
disease.NEnglJMed.2017;376(18):1713–
1722.
Inthisrandomized,double-blind,placebocontrolledtrial(FOURIER)involving27,564
adultswithatheroscleroticcardiovascular
disease,evolocumabresultedinasignificant
reductioninacompositeofcardiovascular
death,myocardialinfarction,stroke,
hospitalizationforunstableangina,orcoronary
revascularization..
MaggeSN,GoodmanE,ArmstrongSC.The
metabolicsyndromeinchildrenandadolescents:
shiftingthefocustocardiometabolicriskfactor
clustering.Pediatrics.2017[Epubaheadof
print].
Anexcellentreviewsummarizingthedifficultiesin
diagnosingthemetabolicsyndromeinchildhood
withanemphasisonshiftingthefocusto
identifyingandtreatingindividual
cardiovascularriskfactors..
MitchellGF,HwangSJ,VasanRS,etal.Arterial
stiffnessandcardiovascularevents:the
FraminghamHeartStudy.Circulation.
2010;121:505–511.
Thisimportantstudydemonstratedpulsewave
velocitytobepredictiveofmajorcardiovascular
diseaseevents,independentofotherCVRFs..
TownsendRR,etal.Recommendationsfor
improvingandstandardizingvascularresearch
onarterialstiffness:ascientificstatementfrom
theAmericanHeartAssociation.Hypertension.
2015;66(3):698–722.
AscientificstatementfromtheAmericanHeart
Associationonimprovingvascularresearchon
arterialstiffness..
UrbinaEM,WilliamsRV,AlpertBS,etal.
Noninvasiveassessmentofsubclinical
atherosclerosisinchildrenandadolescents:
recommendationsforstandardassessmentfor
clinicalresearch:ascientificstatementfromthe
